Moderna announces increase in Covid-19 vaccine supply to 3.0bn doses for 2022
Pharmaceutical company Moderna announced on Thursday additional investments to increase its annual production capacity of Covid-19 vaccines to 3.0bn doses in 2022.
MODERNA
$108.85
13:09 24/04/24
In a statement, the company said the final amount of increased supplies would depend on the exact mix needed between the already authorized Moderna Covid-19 vaccine, at the current dose level, and potentially lower doses of the company’s variant booster candidates and pediatric vaccines, if authorized.
Moderna also said that it would fund those investments, which are set to start in 2021, out of its cash balance.
The investments would allow for a doubling of drug substance manufacturing at Lonza’s Switzerland-based facility, a more than doubling of formulation, fill and finish and drug substance manufacturing at Rovi’s Spain-based facility, and a 50% increase of drug substance from Moderna’s facilities in the US.
When completed, the investments were also expected to result in an increase in the safety stocks of raw materials and finished product used to deliver committed volumes.
The firm also raised its 2021 manufacturing supply forecast to between 800.0m to 1.0bn doses.